<DOC>
	<DOCNO>NCT01633853</DOCNO>
	<brief_summary>It hypothesise efficacy safety Vitamin D2 soft capsule treat Chronic Kidney Disease Mineral Bone Disease ( CKD-MBD ) equal 1,25 ( OH ) 2 Vitamin D3 ( Rocaltrol ) patient CKD stage 3-5 .</brief_summary>
	<brief_title>Efficacy Vitamin D2 Treat Chronic Kidney Disease Mineral Bone Disorder</brief_title>
	<detailed_description>This study enroll chronic kidney disease patient , stage 3 5 , chronic kidney disease mineral bone disease ( CKD-MBD ) define Kidney Disease Improvement Global Outcome ( KDIGO ) Guidelines . Patients one center randomize receive oral Vitamin D2 soft capsule Rocaltrol . A total 200 patient enrol , 100 Vitamin D2 group 100 1,25 ( OH ) 2 Vitamin D3 group . Outcomes assessed proportion patient achieve target blood level calcium , phosphorus , parathyroid hormone , 25 hydroxyvitamin D. Other outcome also assess , include secondary hyperparathyroidism ( sHPT ) , vascular calcification , cardiovascular disease .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Vitamin D Deficiency</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>Patients age 1875 year . Patients chronic kidney disease stage 3 5 , concurrent chronic kidney disease mineral bone disorder . Renal artery stenosis , inherent renal malformation , solitary kidney , malignancy urinary system . New fracture last 3 month . Active system immunity disease . History liver failure History intestinal malabsorption chronic diarrhea Treatment phenobarbital , phenytoin , rifampicin , sucralfate , steroid , digoxin , medication could affect vitamin D metabolism Primary hyperparathyroidism Treatment cinacalcet calcimimetic within past 6 month Anticipated dialysis within 6 month randomization Have unstable medical condition , define hospitalize within 30 day screen , expectation recurrent hospital admission life expectancy le 6 month judgment investigator Subject currently enrol , few 30 day pass since subject complete another investigational device drug study ( ) ; subject receive another investigational agent ( ) . Current treatment vitamin D 50,000 IU Using glucocorticoid immunosuppressive agent . Acute renal dysfunction . The expected live time le 2 year . Pregnant lactate woman . Suffered acute myocardial infraction , acute congestive heart failure , stroke last 6 month . Patients whose concurrent illness , disability , geographical residence would hamper attendance require study visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>chronic kidney disease mineral bone disorder</keyword>
	<keyword>vitamin D2</keyword>
	<keyword>parathyroid hormone</keyword>
</DOC>